3-ethoxycarbonylglutaric dialdehyde | 115973-49-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-ethoxycarbonylglutaric dialdehyde
• 英文别名: 4-oxo-2-(2-oxo-ethyl)-butyric acid ethyl ester；4-oxo-2-(2-oxoethyl)-butanoic acid ethyl ester；4-oxo-2-(2-oxoethyl)butyric acid ethyl ester；β-ethoxycarbonylglutaraldehyde；Ethyl 4-oxo-2-(2-oxoethyl)butanoate
• CAS: 115973-49-4
• 化学式: C₈H₁₂O₄
• 分子量: 172.181
• InChiKey: ZYXAXBVALNQLAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-ethoxycarbonylglutaric dialdehyde 以55.14的产率得到7-ethoxycarbonyl-9-(ethoxycarbonyl-methyl)-9-azabicyclo[3.3.1]nonan-3-one
  参考文献：
  名称：

  WO2007072507A2

  摘要：

  公开号：
• 作为产物：
  描述：

  1-ethoxycarbonyl-3-cyclopenteneoxide 在 过碘酸 作用下， 以 乙酸乙酯 为溶剂， 反应 5.0h， 生成 3-ethoxycarbonylglutaric dialdehyde
  参考文献：
  名称：

  Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof

  摘要：

  本公开涉及一种制备内酯型六氢-8-(3-吲哚基羰氧基)-2,6-甲基-2H-喹唑啉-3(4H)-酮或多拉司琼（Dolasetron）碱的方法。它还公开了一种制备内酯型六氢-8-(3-吲哚基羰氧基)-2,6-甲基-2H-喹唑啉-3(4H)-酮甲磺酸盐或多拉司琼甲磺酸盐的方法。此外，本公开还涉及制备多拉司琼碱的I型晶体，以及多拉司琼碱的新晶体多态形式II、III、IV和V的工业生产过程。

  公开号：

  US20080275241A1

文献信息

• N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS
  申请人：Konradi Andrei W.

  公开号：US20100081680A1

  公开（公告）日：2010-04-01

  The current invention provides compounds having a structure according to Formulae 1, 2, 3, and 4: wherein the A-ring, B-ring, C-ring, m, n, R 25 , R 50 , and R 51 are as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae 1, 2, 3, and 4, as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful in preparing the compounds of Formulae 1, 2, 3, and 4.

  当前发明提供具有根据公式1、2、3和4结构的化合物：其中A环、B环、C环、m、n、R25、R50和R51如说明书所述。该发明还提供了包含公式1、2、3和4化合物的药物组合物，以及治疗认知障碍的方法，如阿尔茨海默病。该发明进一步提供了用于制备公式1、2、3和4化合物的有用的中间体。
• Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0330788A1

  公开（公告）日：1989-09-06

  The present invention is directed to the use of heterocyclic esters of hexahydro-8-hydroxy-2,6-methano-2H-­quinolizin-3(4H)-ones and hexahydro-B-hydroxy-2,6-methano-­2H-quinolizines in the manufacture of cardiac antiarrhythmic agents

  本发明涉及在制造心脏抗心律失常药物中使用六氢-8-羟基-2,6-甲基-2H-喹诺利啉-3(4H)-酮和六氢-B-羟基-2,6-甲基-2H-喹诺利啉的杂环酯。
• New Reagents for the Reductive Quenching of Ozonolysis Reactions
  作者：R. B. Appell、I. A. Tomlinson、I. Hill

  DOI：10.1080/00397919508015494

  日期：1995.11

  Abstract 3,3′-Thiodipropionic acid and its salts were found to be effective reductive quench reagents in the ozonolysis of olefins. They were as effective as methyl sulfide without its drawbacks. A polymer-bound form of 3,3′-thiodipropionic acid was also effective.

  摘要 3,3'-硫代二丙酸及其盐被发现是烯烃臭氧分解中有效的还原猝灭剂。它们与甲基硫醚一样有效而没有其缺点。3,3'-硫代二丙酸的聚合物结合形式也有效。
• Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US04906755A1

  公开（公告）日：1990-03-06

  The present invention is directed to a group of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(3H)-ones and related compounds. The compounds are prepared from the appropriate carboxylic acids and alcohols by standard procedures or, where steric factors are significant, a new process which makes use of heavy metal salts of super acids can be used. The compounds involved are useful in the treatment of migraine and similar disorders and in cytotoxic drug-induced vomiting.

  本发明涉及一组六氢-8-羟基-2,6-甲基-2H-喹噁啉-3(3H)-酮及其相关化合物的酯。这些化合物可以通过标准程序或者在立体因素重要时，可以使用新的过程，利用超酸的重金属盐制备。这些化合物在治疗偏头痛和类似疾病以及细胞毒性药物引起的呕吐方面非常有用。
• Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase
  申请人：Bowers Simeon

  公开号：US20080090817A1

  公开（公告）日：2008-04-17

  The invention provides N-cyclic sulfonamido compounds and salts of Formula I: wherein A is as described in the specification and R 1 and R 2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.

  本发明提供了N-环状磺酰胺化合物和公式I的盐：其中A如规范所述，而R1和R2组合形成[3.3.1]或[3.2.1]环系统，其中氮连接到两个桥头碳，并且[3.3.1]或[3.2.1]环系统可以与杂环芳基或杂环烷基环融合。公式I的化合物可用于治疗或预防认知障碍，如阿尔茨海默病。本发明还包括包含公式I化合物的制药组合物，治疗认知障碍的方法，如阿尔茨海默病，以及制备公式I化合物的中间体。